Taiho Pharmaceutical

Taiho Pharmaceutical Co., Ltd., founded in 1963, is a Japanese specialty pharmaceutical manufacturer and a wholly owned subsidiary of Otsuka Holdings. Headquartered in Tokyo, the company operates within the Pharmaceuticals and Healthcare industries, focusing its extensive research, development, manufacturing, and marketing efforts on prescription medicines. Its primary therapeutic areas include oncology, allergies & immunology, and urology, reflecting a deep commitment to addressing critical unmet medical needs. The company's strategic approach emphasizes innovation and patient-centric solutions across its global operations.

With a workforce ranging from 1,000 to 5,000 employees, Taiho Pharmaceutical maintains a significant international presence, engaging in drug discovery, clinical development, and commercialization across Japan, the United States, Europe, and Asia. This global footprint allows for comprehensive market penetration and diverse research collaborations. To understand the organizational structure and leadership driving these initiatives, one can explore Meet Taiho Pharmaceutical's team. The company's operational scale and commitment to scientific advancement are central to its mission of improving patient outcomes worldwide.

Beyond its prescription drug portfolio, Taiho Pharmaceutical also manages a consumer healthcare business, offering products such as energy and digestive drinks. Its annual revenue stands at approximately $1.4B. The company's integrated ecosystem, from initial drug discovery to commercialization, positions it as a key player in the global pharmaceutical landscape, dedicated to delivering value and advancing medical science for patients.